Not yet recruitingPhase 1NCT07424222

Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE)

Studying Acquired hemophagocytic lymphohistiocytosis associated with malignant disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Principal Investigator
Tania Jain, MBBS
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Intervention
Ruxolitinib(drug)
Enrollment
16 enrolled
Eligibility
18-99 years · All sexes
Timeline
20262028

Collaborators

Incyte Corporation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07424222 on ClinicalTrials.gov

Other trials for Acquired hemophagocytic lymphohistiocytosis associated with malignant disease

Additional recruiting or active studies for the same condition.

See all trials for Acquired hemophagocytic lymphohistiocytosis associated with malignant disease

← Back to all trials